Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DAR-T news coming?
Which of these 12 could produce income over the next 12 months, let alone at any time now!
1. SEMDEXA
2. RTX
3. COVIMARK
4. VIREX
5. Mpro
6. OQORY(COV-MSC)
7. FUJOVEE (Abivertinib) cancer
8. DAR-T cancer
9. ADNAB cancer
10. PD-L1 in China and US
11. SOFUSA, and the special case,
12. PSS arbitration settlement
Clearly there could be a PSS settlement at any time.
All of the other programs are partnerable at any time.
Semdexa revenue will flow 88% to Sorrento.
COVIMARK approval is overdue but they seem to have aggressive marketing plans.
VIREX could be enormous as its tests roll out.
Mpro fills the need for a better, safer, more effective oral broad spectrum antiviral. And it would be easily partnerable!
And I think Sorrento's new powerful Executive VP will make a difference. Let's go Elizabeth!
These remain the top 12 reasons I look for a big gain in Sorrento.( and I think Big Institutions are loading up!). And I DO EXPECT COVID TO CONTINUE.
1. SEMDEXA
2. RTX
3. COVIMARK
4. VIREX
5. Mpro
6. OQORY(COV-MSC)
7. FUJOVEE (Abivertinib) cancer
8. DAR-T cancer
9. ADNAB cancer
10. PD-L1 in China and US
11. SOFUSA, and the special case,
12. PSS arbitration settlement
I think at least 6-8 will be successful.
The potential is multi-billions revenue.
They are partnerable for worldwide sales.
And all should produce news this year!
These remain the top 12 reasons I look for a big gain in Sorrento.( and I think Big Institutions are loading up!). And I DO EXPECT COVID TO CONTINUE.
1. SEMDEXA
2. RTX
3. COVIMARK
4. VIREX
5. Mpro
6. OQORY(COV-MSC)
7. FUJOVEE (Abivertinib) cancer
8. DAR-T cancer
9. ADNAB cancer
10. PD-L1 in China and US
11. SOFUSA, and the special case,
12. PSS arbitration settlement
I think at least 6-8 will be successful.
The potential is multi-billions revenue.
They are partnerable for worldwide sales.
And all should produce news this year!
China, India, Africa and Latin America (beginning in Mexico) all have either poor vaccines or low vaccination rates. Huge world wide market! Scientists say Covid is not going away...but will continue to produce variants which a broad spectrum antiviral could treat!
Testing Mpro in China is a big deal! China has been struggling to contain Covid and would become the worlds largest market for Mpro oral antiviral! Testing Mpro in China is very good news.
"“The trial in China will allow us to evaluate STI-1558 antiviral activity in patients together with safety, tolerability and pharmacokinetics in different dose levels. We are looking forward to seeing the results in COVID-19 patients, which we expect to facilitate our planned STI-1558 Phase II/III trials in Mexico and the U.S.,” stated Henry Ji, Ph.D., President and CEO of Sorrento."
Testing Mpro in China is a big deal! China has been struggling to contain Covid and would become the worlds largest market for Mpro oral antiviral! Testing Mpro in China is very good news.
"“The trial in China will allow us to evaluate STI-1558 antiviral activity in patients together with safety, tolerability and pharmacokinetics in different dose levels. We are looking forward to seeing the results in COVID-19 patients, which we expect to facilitate our planned STI-1558 Phase II/III trials in Mexico and the U.S.,” stated Henry Ji, Ph.D., President and CEO of Sorrento."
MY BIG QUESTION IS WHY ARE THE BIG INSTITUTIONS LOADING UP!
What do they know that us little retailers don't know? 12 possibilities!
1. SEMDEXA
2. RTX
3. COVIMARK
4. VIREX
5. Mpro
6. OQORY(COV-MSC)
7. FUJOVEE (Abivertinib)
8. DAR-T
9. ADNAB
10. PD-L1 in China and US
11. SOFUSA
12. PSS arbitration settlement
It is good to see this deal to market ZTlido in the Middle East and North Africa. What is obvious is that it will be followed by other deals to sell ZTlido in Europe, Asia/Pacific and Latin America. ZTlido is an excellent product. we can expect the same pattern for SEMDEXA, Sp-103 and other products as they roll out.
"Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced an increase of 53% year-over-year preliminary unaudited gross ZTlido sales in March. ZTlido sold $8.1 million in March 2022 compared to $5.3 million in March 2021. In 1Q2022, the preliminary unaudited gross sales for ZTlido are approximately $18.4 million, compared to $14.6 million in 1Q2021, representing a growth of 26%."
March 2022 ZTlido sales exceeded $8.1 million. Annualized that would be $97 million in sales. And sales growth rate was 26%. AROUND $100 million in sales in 2022 is very likely!
ONE QUESTION! WHY ARE THE INSTITUTIONS LOADING UP?
Here are the Sorrento priorities according to the 2Q 2022 ...CANCER, INFECTIOUS DISEASE and PAIN.
"CANCER. Our best-in-category strategy is enabled by combining our fully human G-MAB™ antibody library with our ability to rapidly screen for highly potent and targeted treatments and to enhance the target product profile for these antibodies by leveraging our extensive proprietary immuno-oncology platforms such as immuno-cellular therapies (“DAR-T™”), antibody-drug conjugates (“ADCs”), oncolytic virus (“Seprehvec™”) and lymphatic drug delivery (“Sofusa™”).
INFECTIOUS DISEASE. We have applied our antibody capability in the fight against COVID-19. We are developing highly sensitive and rapid diagnostics, and multi-model treatments for the SARS-CoV-2 virus and its variants. Our diagnostics platforms include the COVIMARK™ lateral flow antigen test (launched as COVISTIX™ in Mexico and Brazil), COVITRACK, a LAMP-based pathogen nucleic acid detection assay, and the VIREX™ platform, which leverages existing worldwide manufacturing infrastructure for glucometers and glucose strip tests to provide affordable and highly scalable, next-generation diagnostic solutions for infectious diseases, liver cancer and other biomarkers. We are also focused on bringing forward effective therapeutic solutions, including a next generation protease inhibitor antiviral pill, COVISHIELD™ IN (neutralizing antibody nasal drops) and variant agnostic rescue therapies, FUJOVEE ™ (Abivertinib) and OQORY™ (mesynstromal stem cells).
PAIN. We are focusing our efforts on non-opioid and non-addictive pain treatments. The flagship product of our pain programs, ZTlido®, is being marketed by Scilex Pharmaceuticals Inc. (“Scilex Pharma”), our majority-owned subsidiary. ZTlido was launched in October of 2018 as a prescription lidocaine topical product and has demonstrated superior adhesion and bioavailability compared to current lidocaine patches. Scilex Pharma has now built a full commercial organization, which includes sales, marketing, market access and medical affairs, and will leverage capability for the potential launch of next-generation products that are currently in development. The first of these product candidates, SEMDEXA™, is an injectable viscous gel formulation of a widely used corticosteroid designed to address the limitations associated with off label corticosteroid epidural injections. We announced positive final results for the Phase 3 trial for SEMDEXA™ in March 2022.
We are also developing Resiniferatoxin (“RTX”), a naturally occurring and ultra-potent transient receptor potential vanilloid-1 agonist. When injected peripherally, a sustained desensitization occurs, resulting in reduction of noxious chronic pain symptoms that can last for months. RTX has the potential to be a multi-indication franchise asset and is nearing pivotal studies in intractable pain associated with cancer and moderate to severe knee osteoarthritis pain.
Second quarter pipeline product development and business updates
•
In June 2022, Scilex Holding entered into a license and commercialization agreement with RxOmeg Therapeutics, LLC for the exclusive right to market and distribute in the US Gloperba, an oral solution for adults suffering from gout."
Maybe the Institutions are already pulling the strings!
Institutions with 40% of shares will find it easy to capture retail support!
My guess is that they are already in control by insisting on the new very powerful EXEC VP! And they could be behind the Tommy Thompson appointment!. Both of those moves were very unJi like! He is not a power sharer!
1776...Let's say they could post Friday or Monday.
If they post on a Friday, critics would say that was an attempt to sneak the news through when people are not interested in the market.
If they post on Monday, will critics admit that it was because they had good news?
Why are Institutions buying so aggressively?
It is a mystery!
BLACKROCK just added aprox 12 milions shares!!
https://fintel.io/sob/us/srne
40 million shares...what do they know?
Mpro is advancing rapidly! Could be receiving EUA's by this winter.
"The multiple ascending dose (MAD) study is starting in Australia. A large Phase 2 study is planned in Mexico that could support an Emergency Use Authorization (EUA) in Mexico. Phase 2/3 trials in US and other major regions have also been planned once the MAD part is successfully completed."
Potential $20 Billion market!
I expect a lot of news in 2H 2022...many potential partnerships!.
1. SEMDEXA
2. RTX
3. COVIMARK
4. VIREX
5. Mpro
6. OQORY(COV-MSC)
7. FUJOVEE (Abivertinib)
8. DAR-T
9. ADNAB
10. PD-L1 in China and US
11. SOFUSA
12. PSS arbitration settlement
New July Corporate Presentation. Mpro and Virex are highlighted. Both are potential blockbusters and are clearly the new priority!
https://investors.sorrentotherapeutics.com/static-files/ded13448-aa64-4405-a2d9-de644cfe9dfc
Here is some background on Sorrento's Mpro drug licensed from Texas A&M. It compares favorably with Merk's drug according to this news release. It will be nice to see more about a comparison to the Pfizer drug.
Sorrento Exercises Exclusive Option Agreement With Texas A&M University for MPRO Inhibitors Against Sars-Cov-2 and all Variants of Concern
August 26, 2021 15:42 ET | Source: Sorrento Therapeutics, Inc.
*Exclusive license for MPro inhibitors supports rapidly growing small molecule development portfolio for combating COVID-19.
**Lead compound, MPI8, exhibited potent in vitro antiviral activity against SARS-CoV-2 and all of the major Variants of Concern (VoCs) (alpha, beta, delta and gamma).
*MPI8 also demonstrated superior antiviral activity in a head-to-head comparison with a late-stage clinical antiviral compound (EIDD-2801).
Based on the IC50 data of the Plague Reduction Neutralization Test (PRNT) of live virus infecting Vero E6 cells, MPI8 demonstrated approximately ten-fold (10x) higher antiviral potency than EIDD-2801 against SARS-CoV-2 and its Alpha (UK) and Delta (Indian) VoCs and three to seven-fold (3-7x) higher antiviral potency against Beta (South Africa, 3X) and Gamma (Brazil/Japan, 6-7X) VoCs.
SAN DIEGO, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it has notified The Texas A&M University System (“TAMUS”) of its exercise of the option to an exclusive license for the global development and commercialization of highly potent main protease (MPro) inhibitors against SARS-CoV-2 and all current and emerging variants of concern (VOCs). Sorrento and TAMUS previously announced the signing of the option agreement on August 24th and 25th, respectively:
https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-announces-entry-option-agreement
https://today.tamu.edu/2021/08/25/texas-am-researcher-new-drug-could-be-game-changer-against-covid-19
Sorrento’s decision to immediately exercise its option is based on very promising preclinical data for the lead compound, MPI8, that shows highly potent broad-spectrum antiviral activity against SARS-CoV-2 and all of the major Variants of Concern (VoCs) (alpha, beta, delta and gamma). Based on initial in vitro data, MPI8 demonstrated superior antiviral activity in a head-to-head comparison with a current Phase 3 investigational oral antiviral agent (EIDD2801). Based on the IC50 data of the Plague Reduction Neutralization Test (PRNT) of live virus infecting Vero E6 cells, MPI8 demonstrated approximately ten-fold (10x) higher antiviral potency than EIDD-2801 against SARS-CoV-2 and its Alpha (UK) and Delta (Indian) VoCs and three to seven-fold (3-7x) higher antiviral potency against Beta (South Africa, 3X) and Gamma (Brazil/Japan, 6-7X) VoCs.
Sorrento expects to complete additional preclinical studies in the coming weeks, including a head-to-head comparison against other late-stage clinical candidates, and will publish its preliminary findings in a pre-print publication."
Some predict Pfizer's drug could garner more than $20 Billion in sales.
Sorrento's Mpro drug could be more effective, safer(no drug/drug interactions) and cheaper(no costly adjuvant needed)!
Win, Win, Win!
Dosing trials have moved rapidly in Australia...and Australia has generous funding assistance for drug trials!
Here is a scientific article which discusses the dual action of the family of anti-virals of which Sorrento's STI-1558 is a good example. It is good to see the trials advancing rapidly. The potential is huge!
https://medicalxpress.com/news/2020-11-reveals-strategy-covid-drugs-inhibit.html
Jess there has not been much exciting news...but this could be very big!
The advance of Sorrento's Mpro drug is very exciting. The dosing study in Australia is well advanced. They want to establish a MTD. And it looks like the effective dose is going to be well under that. Very good safety margin!
And it appears to be able to avoid the drug/drug interaction problem that limits the Pfizer drug.
I could see the pivotal phase 2/3 worldwide study being partnered with a BP for EUA application and world wide marketing.
WITH A POTENTIAL COVID EXPLOSION NEXT WINTER THIS COULD BE A BLOCKBUSTER...MEETING A HUGE NEED!
Might this actually be coming to a conclusion?
rtx7
Bullish
7/10/22, 03:59 PM
$SRNE
I wouldn't go window shopping for Lambo's over this next point, but as @ididathing9999 previously uncovered, "Summations" in the PSS Cynviloq arbitration are scheduled for "mid-July 2022" according to the most recent IBRX 10-Q filing.
--The parties completed post-hearing briefing in early May 2022, and summations are scheduled for mid-July 2022.--
How do summations in arbitration typically work?
avvo.com/legal-guides/ugc/w...
--After summations, the arbitrator must ask the parties if they have any final arguments, evidence or witnesses to present. When the disputants are satisfied with the presentations of their cases, the arbitrator declares the proceedings officially closed. Arbitration rules usually specify the time the arbitrator has to render a decision. This period begins after the proceedings are declared closed. If no time has been specified, some state statutes require that the award be made within 30 days.....
....and the "coming soon" is interesting.
Repost of Stocktwit: SRNE Videos
https://vimeo.com/user151377019
I'm still holding on. In fact I added shares. Not much exciting news yet!
However I like the institutional buyers...and the new appointment of Queen Elizabeth...and wonder if they are linked?
1776...why would the new VP / CFO come on board and Blackrock and State Street make such massive purchases? They must know more than we do?
cheynew, who I know from several other stocks, ask me if I still hold SRNE. I do. In fact I have added. I like to hold stocks that I think have a 10 bagger potential. SRNE is one example. ATNM is another. etc.
During the biotech slump I have been adding. But I also have spent more time watching basketball and baseball....only to discover that they are equally frustrating!
There are many near term catalysts...
1.Topline SIERRA data Q3 2022 (July?) already Orphan Drug Status in US and Europe
2.US and ROW Sierra partnership 2022
3. SIERRA BLA filing 1H 2023
4.Iomab-ACT CAR-T data 2022
5. GeneTx data 2022
6.Actimab-A + CLAG update 1H 2022
7.Actimab-A + Venetudax ph.2 1H 2022
8.AWE platform advances 2022
The very attractive European partnership should be followed by an US and ROW partnership. Or perhaps by a BO. Astellas is the 1000 lb. Gorilla in the room. If they like what they have seen so far they could buy up the whole company for a few $Billion. They have multi-Billions in cash! Chicken feed for them...but a nice return for Actinium investors!
No wonder H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report) and set a price target of $45.00.
Truly impressive results. And this was in heavily pretreated patients. It would be great to advance it to first line!
She has power. She has experience. She has connections.It is the kind of change that may not attract attention but can have profound effects!
She will oversee ALL ASPECTS of not only Scilex but also SORRENTO management
Don't overlook this. "overseeing ALL ASPECTS " of SORRENTO finances, communications and business development!
" Ms. Czerepak will be a member of the Scilex and Sorrento Executive Leadership Teams, reporting to Scilex’s Chief Executive Officer and President, Jaisim Shah, and Sorrento’s Chief Executive Officer, Henry Ji, overseeing all aspects of Scilex and Sorrento’s financial management, corporate communications and corporate and business development areas. "
And don't overlook ZTlido, the ugly stepchild everyone ignores. Revenue in March was up over 50% from previous year, and annual sales should exceed $100 million IMO.
As with all the presentations...you have to sift through the chaff to retrieve the kernels . Such as...they have already already applied for BTD for SEMDEXA! We should hear more next month. And the Scilex man gave some interesting information on SEMDEXA and several of the other drugs in their portfolio.
April 27 2022 Presentation on pipeline and Scilex products.
https://www.webcaster4.com/Webcast/Page/2875/45350
There are many near term milestones.
1.Topline SIERRA data Q3 2022 (July?) already Fast Tracked in US and Europe
2. SIERRA BLA filing 1H 2023
3.Iomab-ACT CAR-T data 2022
4. GeneTx data 2022
5.Actimab-A + CLAG update 1H 2022
6.Actimab-A + Venetudax ph.2 1H 2022
7.AWE platform advances 2022
The very attractive European partnership should be followed by an US and ROW partnership. Or perhaps by a BO. Astellas is the 1000 lb. Gorilla in the room. If they like what they have seen so far they could buy up the whole company for a few $Billion. Chicken feed for them...but a nice return for Actinium investors!
No wonder H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report) and set a price target of $45.00.
I'll try posting the April 2022 Corporate Presentation again. The portfolio is very large. The current European partnership is very good...but it is only the beginning.
https://d1io3yog0oux5.cloudfront.net/_ff332a9fcd49f05da0cf4d0090c6f388/actiniumpharma/db/206/944/pdf/Actinium_Investor+Presentation_April+25+2022_.pdf
This is troubling...
PARIS: Not even one in three people have completely recovered from COVID-19 a full year after being hospitalised with the disease, a United Kingdom study indicated on Sunday (Apr 24), warning that long COVID could become a common condition.
The study involving more than 2,300 people also found that women were 33 per cent less likely to fully recover than men.
It also found that obese people were half as likely to fully recover, while those who needed mechanical ventilation were 58 per cent less likely.
The study looked at the health of people who were discharged from 39 British hospitals with COVID-19 between March 2020 and April 2021, then assessed the recovery of 807 of them five months and one year later.
Just 26 per cent reported a full recovery after five months, and that number rose only slightly to 28.9 per cent after a year, according to the study published in the Lancet Respiratory Medicine journal.
"The limited recovery from five months to one year after hospitalisation in our study across symptoms, mental health, exercise capacity, organ impairment and quality of life is striking," said study co-leader Rachel Evans of the National Institute for Health and Care Research.
The most common long COVID symptoms were fatigue, muscle pain, poor sleep, slowing down physically and breathlessness.
"Without effective treatments, long COVID could become a highly prevalent new long-term condition," said study co-lead Christopher Brightling of the University of Leicester.
The study, which will be presented at the European Congress of Clinical Microbiology and Infectious Diseases, is ongoing, and will continue to monitor the patients' health.